<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05006950</url>
  </required_header>
  <id_info>
    <org_study_id>CRD10283</org_study_id>
    <nct_id>NCT05006950</nct_id>
  </id_info>
  <brief_title>SPY Fluorescence Imaging Systems and Indocyanine Green as a Tool for Developing Intelligent Peri-Operative Imaging</brief_title>
  <acronym>Smart Imaging</acronym>
  <official_title>SPY Fluorescence Imaging Systems and Indocyanine Green as a Tool for Developing Intelligent Peri-Operative Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stryker Endoscopy</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stryker Endoscopy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective single arm, single center study estimating percentage of successful&#xD;
      critical anatomy recognition in laparoscopic cholecystectomy surgeries using SPY fluorescence&#xD;
      imaging and ICG to develop intelligent imaging tools (I-IT), with each surgery also providing&#xD;
      a white light 360 degree images.&#xD;
&#xD;
      The primary objective is to determine the percentage of successful critical anatomy&#xD;
      recognition using intra-operative SPY fluorescence imaging and ICG: and to describe&#xD;
      complications associated with intra-operative decision making in patients undergoing&#xD;
      laparoscopic cholecystectomy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 28, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Outcome 1</measure>
    <time_frame>Intra-op visit</time_frame>
    <description>To determine the percentage of successful critical anatomy recognition using intra-operative SPY fluorescence imaging and ICG in subjects undergoing laparoscopic cholecystectomy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Outcome 2</measure>
    <time_frame>Intra-op visit</time_frame>
    <description>To estimate the number of times a surgeon altered the surgical plan due to information identified/revealed by SPY fluorescence imaging</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Outcome 3</measure>
    <time_frame>Post op follow- up (7-14 days)</time_frame>
    <description>To estimate the number of post-operative complications (related to gall bladder surgery</description>
  </other_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cholecystitis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stryker1688 Fluorescence imaging system</intervention_name>
    <description>The purpose of this study is to use SPY fluorescence imaging systems and indocyanine green (ICG) as a tool for developing intelligent peri-operative imaging by determining the percentage of successful critical anatomy recognition and to describe complications associated with intra-operative decision making in patients undergoing laparoscopic cholecystectomy.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is 18 years of age or older&#xD;
&#xD;
          -  Subject is scheduled to undergo laparoscopic cholecystectomy, elective or emergent&#xD;
&#xD;
          -  Subject provides informed consent and signs an approved informed consent document for&#xD;
             the study&#xD;
&#xD;
          -  Subject is willing to comply with the protocol and study visit schedule&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is pregnant or lactating&#xD;
&#xD;
          -  Subject has a known allergy or history of adverse reaction to ICG, iodine or iodine&#xD;
             dyes&#xD;
&#xD;
          -  Subject has known history of cholangitis, pancreatitis, prior bile duct injury,&#xD;
             coagulopathy or known pre-existing liver disease&#xD;
&#xD;
          -  Subjects who, in the Investigator's opinion, have any medical condition that may make&#xD;
             the subject a poor candidate for the investigation, interferes with the interpretation&#xD;
             of study results, or integrity of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Prajakta Sawwalakhe, M.D</last_name>
    <phone>408-646-8950</phone>
    <email>prajakta.sawwalakhe@stryker.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alicia Wilton</last_name>
    <email>alicia.wilton@stryker.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Anne Arundel Medical Center</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Harris</last_name>
      <email>eharris2@aahs.org</email>
    </contact>
    <investigator>
      <last_name>Adrian Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Klune Robert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 9, 2021</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecystitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

